Cellectis Operating Margin from 2010 to 2024
| CLLS Stock | USD 2.10 0.03 1.41% |
Check Cellectis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cellectis' main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.4 M, Interest Expense of 6.7 M or Selling General Administrative of 30.4 M, as well as many indicators such as Price To Sales Ratio of 223, Dividend Yield of 0.0 or PTB Ratio of 3.61. Cellectis financial statements analysis is a perfect complement when working with Cellectis Valuation or Volatility modules.
Cellectis | Operating Margin |
Latest Cellectis' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Cellectis SA over the last few years. It is Cellectis' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cellectis' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.60) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Cellectis Operating Margin Regression Statistics
| Arithmetic Mean | (19.22) | |
| Coefficient Of Variation | (225.34) | |
| Mean Deviation | 28.38 | |
| Median | (1.90) | |
| Standard Deviation | 43.30 | |
| Sample Variance | 1,875 | |
| Range | 129 | |
| R-Value | (0.61) | |
| Mean Square Error | 1,277 | |
| R-Squared | 0.37 | |
| Significance | 0.02 | |
| Slope | (5.87) | |
| Total Sum of Squares | 26,253 |
Cellectis Operating Margin History
About Cellectis Financial Statements
Cellectis shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Cellectis investors may analyze each financial statement separately, they are all interrelated. The changes in Cellectis' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cellectis' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 294 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.